Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Philogen SpA ( (IT:PHIL) ) has issued an announcement.
Philogen S.p.A. has announced an update on its share buyback program, purchasing 4,444 shares between February 3 and February 7, 2025, at an average price of Euro 17.9958 per share. This is part of a broader initiative that has seen the company buy 22,041 shares since the program’s inception, reflecting Philogen’s commitment to enhancing shareholder value and its strategic financial management.
More about Philogen SpA
Philogen is an Italian-Swiss biotechnology company specializing in the research and development of pharmaceutical products for treating diseases with high mortality rates. The company focuses on discovering and developing targeted anti-cancer drugs using high-affinity ligands for tumor markers, primarily through tumor targeting and vascular targeting approaches.
YTD Price Performance: -9.21%
Average Trading Volume: 277
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €541M
For an in-depth examination of PHIL stock, go to TipRanks’ Stock Analysis page.
